20/20 Biolabs, Inc. (AIDX)
NASDAQ: AIDX · Real-Time Price · USD
0.4220
+0.0130 (3.18%)
Sep 29, 2026, 1:49 PM EDT - Market open
20/20 Biolabs Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -5.81 | -3.74 | -5.55 | -6.39 | 2.19 | 2.07 |
Depreciation & Amortization | 0.08 | 0.09 | 0.14 | 0.17 | 0.29 | 0.12 |
Other Amortization | 0.63 | 0.12 | 0 | 0.01 | 0 | - |
Loss (Gain) From Sale of Assets | - | - | - | - | 0 | - |
Asset Writedown & Restructuring Costs | - | - | 0.02 | 0.21 | 0.02 | - |
Stock-Based Compensation | 0.94 | 0.52 | 2.18 | 1.3 | 0.18 | 0.18 |
Other Operating Activities | 0.73 | 0.27 | -0 | - | - | -0.14 |
Change in Accounts Receivable | -0.12 | -0.06 | -0.07 | 0.7 | 1.94 | -4.01 |
Change in Inventory | -0.05 | -0.07 | 0.01 | 0.03 | 0.16 | -0.14 |
Change in Accounts Payable | 0.47 | 0.5 | 0.01 | -0.1 | -0.25 | 0.36 |
Change in Unearned Revenue | 0.07 | -0.06 | 0.27 | -0.06 | 0.16 | 0.08 |
Change in Other Net Operating Assets | 0.26 | 0.54 | 0.4 | -0.33 | 1.11 | 0.4 |
Operating Cash Flow | -2.79 | -1.92 | -2.6 | -4.48 | 5.8 | -1.07 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | - | - | -0.01 | -0.26 | -0.23 |
Sale of Property, Plant & Equipment | - | - | - | - | 0.01 | - |
Sale (Purchase) of Intangibles | -0.01 | - | - | -0.03 | -0.21 | - |
Investing Cash Flow | -0.01 | - | - | -0.04 | -0.46 | -0.23 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | 0.99 | - | - | 0.18 | - |
Total Debt Issued | 1.17 | 0.99 | - | - | 0.18 | - |
Long-Term Debt Repaid | - | - | - | -0.05 | -0.06 | -0.06 |
Total Debt Repaid | - | - | - | -0.05 | -0.06 | -0.06 |
Net Debt Issued (Repaid) | 1.17 | 0.99 | - | -0.05 | 0.12 | -0.06 |
Issuance of Common Stock | 0 | 0 | - | 0 | 0 | 0 |
Other Financing Activities | -0.85 | -0.02 | - | -0.15 | -0.01 | 0 |
Financing Cash Flow | 6.33 | 1.16 | 0.29 | -0.19 | 0.11 | 1.19 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | 3.52 | -0.76 | -2.31 | -4.72 | 5.45 | -0.11 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2.79 | -1.92 | -2.6 | -4.49 | 5.54 | -1.3 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -136.84% | -93.87% | -148.30% | -315.20% | 50.11% | -13.53% |
Free Cash Flow Per Share | -0.39 | -0.39 | -0.54 | -0.94 | 0.58 | -0.14 |
Levered Free Cash Flow | -0.81 | -0.63 | -0.92 | -2.43 | 4.02 | - |
Unlevered Free Cash Flow | -1 | -0.65 | -0.92 | -2.42 | 4.03 | - |